[
  {
    "id": "principle",
    "label": "PRINCIPLE",
    "platform": "PRINCIPLE",
    "country": "UK",
    "dose_ug_kg_day": [
      300,
      400
    ],
    "duration_days": 3,
    "blinded": false,
    "reference": "doi:10.1016/j.jinf.2024.106130",
    "pmcid": "PMC10981761",
    "source_locator": "Table 2, concurrent and eligible analysis population",
    "analysis_population": "SARS-CoV-2 positive with follow-up; concurrent and eligible usual-care controls",
    "analysis_n_t": 2157,
    "analysis_n_c": 1806,
    "followup_days": 28,
    "endpoint": "COVID-19-related hospitalization or death",
    "events_t": 34,
    "n_t": 2157,
    "events_c": 27,
    "n_c": 1806,
    "primary_pool": true,
    "recovery": {
      "endpoint": "time to first self-reported recovery",
      "metric": "adjusted hazard ratio, faster recovery above 1",
      "estimate": 1.15,
      "lower": 1.06,
      "upper": 1.24,
      "interval": "95% Bayesian credible interval",
      "population": "concurrent and eligible sensitivity analysis"
    },
    "other_control": {
      "description": "all usual-care controls, including pre-ivermectin enrollment",
      "events_c": 144,
      "n_c": 3256
    },
    "notes": "Open-label. Primary paper models temporal drift; raw all-control counts are not a randomized contemporaneous treatment contrast. Treatment recruitment June 23 2021 to July 1 2022; broader platform earlier. Baseline concurrent eligible randomized N=2250/1869, analysis N=2157/1806.",
    "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10981761/",
    "retrieved_utc": "2026-10-07",
    "retrieved_source_sha256": "3a193ac8cb4cae95096fe1d15809ca6b04880d8c1bbdd2ea40bb3939e3dd9711"
  },
  {
    "id": "activ400",
    "label": "ACTIV-6 lower dose",
    "platform": "ACTIV-6",
    "country": "US",
    "dose_ug_kg_day": 400,
    "duration_days": 3,
    "blinded": true,
    "reference": "doi:10.1001/jama.2022.18590",
    "pmcid": "PMC9587497",
    "source_locator": "Table 2, hospitalization or death through day 28",
    "analysis_population": "Eligible randomized participants receiving study drug; concurrent eligible placebo",
    "analysis_n_t": 817,
    "analysis_n_c": 774,
    "followup_days": 28,
    "endpoint": "all-cause hospitalization or death",
    "events_t": 10,
    "n_t": 817,
    "events_c": 9,
    "n_c": 774,
    "primary_pool": true,
    "recovery": {
      "endpoint": "time to sustained recovery, three consecutive symptom-free days",
      "metric": "adjusted hazard ratio, faster recovery above 1",
      "estimate": 1.07,
      "lower": 0.96,
      "upper": 1.17,
      "interval": "95% Bayesian credible interval",
      "population": "full analysis, skeptical prior"
    },
    "notes": "Enrollment June 23 2021 through February 4 2022. Contemporaneous contributing placebo allowed. Correction January 10 2023 addresses sites, grant, figure and investigator; current source used.",
    "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9587497/",
    "retrieved_utc": "2026-10-07",
    "retrieved_source_sha256": "92f823fad8074249bf84406114eda11c43ed6cff1b340b61c778903708d78e41"
  },
  {
    "id": "activ600",
    "label": "ACTIV-6 higher dose, corrected",
    "platform": "ACTIV-6",
    "country": "US",
    "dose_ug_kg_day": 600,
    "duration_days": 6,
    "blinded": true,
    "reference": "doi:10.1001/jama.2023.1650",
    "pmcid": "PMC9941969",
    "source_locator": "Corrected Table 2, hospitalization or death through day 28",
    "analysis_population": "Eligible randomized participants receiving study drug; concurrent eligible placebo",
    "analysis_n_t": 708,
    "analysis_n_c": 724,
    "followup_days": 28,
    "endpoint": "all-cause hospitalization or death",
    "events_t": 7,
    "n_t": 708,
    "events_c": 2,
    "n_c": 722,
    "primary_pool": true,
    "recovery": {
      "endpoint": "time to sustained recovery, three consecutive symptom-free days",
      "metric": "adjusted hazard ratio, faster recovery above 1",
      "estimate": 1.02,
      "lower": 0.92,
      "upper": 1.12,
      "interval": "95% Bayesian credible interval",
      "population": "corrected full analysis, skeptical prior"
    },
    "notes": "May 16 2024 correction restored 226 erroneously excluded participants. Table header has placebo N=724, endpoint denominator is explicitly 722. One ivermectin-arm death was an accident unrelated to COVID or treatment. Recruitment February 16 to July 22 2022, disjoint in time from lower-dose cohort.",
    "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9941969/",
    "retrieved_utc": "2026-10-07",
    "retrieved_source_sha256": "1237afe672b0732832072a3e47e346bcc18ffd401bc08239b6956fbe36cf0389"
  },
  {
    "id": "covidout",
    "label": "COVID-OUT",
    "platform": "COVID-OUT",
    "country": "US",
    "dose_ug_kg_day": [
      390,
      470
    ],
    "duration_days": 3,
    "blinded": true,
    "reference": "doi:10.1056/NEJMoa2201662",
    "pmcid": "PMC9945922",
    "source_locator": "resultsSection/outcomeMeasuresModule/outcomeMeasures/2; Progression, 28 days; groups OG002 and OG003",
    "analysis_population": "Modified intention-to-treat, received study drug; concurrent randomized controls; factorial metformin allocation",
    "analysis_n_t": 410,
    "analysis_n_c": 398,
    "followup_days": 28,
    "endpoint": "hospitalization or death",
    "events_t": 4,
    "n_t": 374,
    "events_c": 5,
    "n_c": 356,
    "primary_pool": true,
    "recovery": null,
    "published_adjusted_hospital_death": {
      "estimate": 0.73,
      "lower": 0.19,
      "upper": 2.77,
      "metric": "odds ratio",
      "interval": "95% confidence interval"
    },
    "notes": "Day-28 counts and endpoint denominators come from the public registry, not the day-14 journal table. Crude available-case risks do not reconstruct adjusted or imputed trial analyses. The registry does not specify individual reasons for the denominator reduction.",
    "source_url": "https://clinicaltrials.gov/study/NCT04510194?tab=results",
    "retrieved_utc": "2026-10-13",
    "retrieved_source_sha256": "67255f0eb7f5a0d4a7bc7ea8b35d27dd77dddd485b9382616a1b9c8f76c4a956"
  },
  {
    "id": "together",
    "label": "TOGETHER",
    "platform": "TOGETHER",
    "country": "Brazil",
    "dose_ug_kg_day": 400,
    "duration_days": 3,
    "blinded": true,
    "reference": "doi:10.1056/NEJMoa2115869",
    "pmcid": "PMC9006771",
    "source_locator": "Table 2, intention-to-treat primary outcome",
    "analysis_population": "Intention-to-treat, concurrent randomized placebo",
    "analysis_n_t": 679,
    "analysis_n_c": 679,
    "followup_days": 28,
    "endpoint": "COVID-19 hospitalization or emergency observation longer than 6 hours",
    "events_t": 100,
    "n_t": 679,
    "events_c": 111,
    "n_c": 679,
    "primary_pool": false,
    "recovery": {
      "endpoint": "time to clinical recovery",
      "metric": "hazard ratio, faster recovery above 1",
      "estimate": 1.05,
      "lower": 0.88,
      "upper": 1.24,
      "interval": "95% Bayesian credible interval",
      "population": "intention-to-treat"
    },
    "hospital_only": {
      "events_t": 79,
      "events_c": 95,
      "n_t": 679,
      "n_c": 679
    },
    "death_only": {
      "events_t": 21,
      "events_c": 24,
      "n_t": 679,
      "n_c": 679
    },
    "notes": "Primary composite contains prolonged emergency observation; not the same as hospitalization or death. Hospitalization and death margins alone do not identify their union because overlap is not reported in Table 3. Kept separate from primary and mixed-window pools.",
    "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9006771/",
    "retrieved_utc": "2026-10-07",
    "retrieved_source_sha256": "dceeddc5bf37227312f921136300561ed153b4320e37cafde6f3b62bc2616c78"
  }
]